

Press release

Manila, Philippines 31 Jan 2020

Scandinavian ChemoTech reaches a new milestone by introducing IQwave™ and D-EECT treatment at state hospitals in the Philippines

This week ChemoTech reached an important milestone by introducing the IQwave™ and educating doctors at three government hospitals in the Philippines

ChemoTech's CEO and our new distributor in the Philippines, Basemed, conducted introductions and training of doctors at three of the most important state hospitals in Manila and Davao during this week. The first training was conducted on Tuesday, January 28th at the Jose Reyes Memorial and on Wednesday the second was conducted at Philippine General Hospital (PGH). The training week ended at the Southern Philippines Medical Center (SPMC) in Davao. During these three days, 60 doctors from surgical, medical and radiologic oncology participated in the training.

The focus of the collaboration, with all three hospitals, is to lift IQwave™ and the D-EECT treatment into the academic world in the Philippines and thus get more clinical data on the D-EECT treatment for various indications. It is also an important step in our long-term strategy for getting D-EECT included in the public health insurance.

"Completing training and education at these state hospitals in the Philippines is a very important step in making IQwave™ and our D-EECT treatment available in the future arsenal in the fight against cancer in this country" - Mohan Frick, CEO

For more info, please contact:

Mohan Frick, CEO

Tele: +46 (0)10-218 93 00

Mail: info@chemotech.se

Certified Adviser: Västra Hamnen Corporate Finance AB, Tel: +46 40 200 250,

E-mail: ca@vhcorp.se

Scandinavian ChemoTech AB (publ)

ChemoTech is a Swedish medical technology company based in Lund that has developed a patented technology platform to offer cancer patients access to a new treatment alternative, tumour specific electroporation, available for treatment of both humans and animals. There are a large number of cancer patients whose tumours for various reasons cannot be treated by conventional methods but where tumour specific electroporation can be a solution. Therefore, the company continuously evaluates new opportunities and areas of application for the technology. ChemoTech's shares (CMOTEC B) are listed on Nasdaq First North Growth Market in Stockholm and Västra Hamnen Corporate Finance AB is the company's Certified Adviser. Read more at: www.chemotech.se.